Preclinical News and Research

RSS

Blood markers can indicate people at risk of developing ulcerative colitis

Researchers at örebro University have identified blood markers that can indicate who is at risk of developing ulcerative colitis - a chronic inflammatory bowel disease - later in life.

20 Feb 2026

Remote-controlled CAR T cells offer safer cancer therapy

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers.

19 Feb 2026

Gut microbiome may shape response to GLP-1 drugs, new review suggests

This review examines how GLP-1 receptor agonists and the gut microbiome influence one another through bile acid signaling, short-chain fatty acids, and inflammatory pathways. It explores how microbial composition may shape treatment response and highlights the need for controlled human studies to enable microbiome-informed precision therapy.

19 Feb 2026

Axol Bioscience acquires ophthalmology business from Newcells Biotech

Axol Bioscience Ltd. (Axol), a leading provider of induced pluripotent stem cell (iPSC) technologies for drug discovery and research, today announced that it has acquired the ophthalmology business of Newcells Biotech (Newcells), a leading drug discovery partner specializing in the development of in vitro models and bespoke assay services.

18 Feb 2026

Can GLP-1 drugs slow neurodegeneration? New review finds promising signals but limited clinical proof

This review examines how GLP-1 receptor agonists may influence neurodegenerative disease biology through metabolic, inflammatory, mitochondrial, and proteostasis pathways. Evidence from mechanistic, preclinical, and early clinical studies suggests potential neuroprotective effects, but definitive disease-modifying benefit remains unproven.

17 Feb 2026

Insilico Medicine and MSK collaborate to discover new drug targets for gastroesophageal malignancies

Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and Memorial Sloan Kettering Cancer Center (MSK) have entered into a collaborative research agreement aimed at discovering new therapeutic targets for gastroesophageal malignancies.

17 Feb 2026

A yeast-derived genetic tool offers hope for mitochondrial disorders and cancer

Nucleotide synthesis-the production of the basic components of DNA and RNA-is essential for cell growth and division.

17 Feb 2026

Chronic inflammation shapes cancer progression and immunotherapy response

Chronic inflammation is both a driver and suppressor of cancer depending on context. Key players-NF-κB, IL-6, STAT3, TAMs, MDSCs, and Tregs-orchestrate a tumor-permissive microenvironment.

16 Feb 2026

OVACell project pioneers viral target immunotherapy for ovarian cancer

A small team at OVACell is fighting ovarian cancer with hidden viral sequences and advanced immunotherapies.

16 Feb 2026

Synergistic drug pair shows promise for spinal cord injury recovery

Spinal cord injury remains one of the most challenging neurological conditions to treat, largely because damage continues to worsen long after the initial trauma.

16 Feb 2026

Study explores how reversible RNA editing could transform future cardiovascular medicine

This mini-review synthesises evidence showing that adenosine-to-inosine RNA editing plays an important regulatory role in cardiovascular development, cellular homeostasis, and disease biology. It highlights emerging links between dysregulated RNA editing and cardiovascular conditions while outlining biomarker potential and reversible RNA-editing therapeutic strategies that remain under investigation.

15 Feb 2026

Role of food nutrients in reducing oxidative stress linked to micro- and nanoplastics

This narrative review examines how micro- and nanoplastics may contribute to oxidative stress, inflammation, and metabolic dysfunction, including potential links with diabetes. It highlights plant-derived nutrients that activate the Nrf2 pathway as a possible strategy to enhance cellular stress resilience, although most evidence remains preclinical.

15 Feb 2026

Novel antibody 007 targets the elusive HIV envelope epitope

HIV-1 can be neutralized by antibodies which bind to vulnerable structures on the virus surface. One such vulnerable site is the so-called V3 glycan site of the viral envelope protein.

13 Feb 2026

Diacerein shows promise as disease-modifying therapy in rheumatoid arthritis

Announcing a new publication for Acta Materia Medica journal. Diacerein, an anthraquinone derivative, is emerging as a promising disease-modifying agent in rheumatoid arthritis (RA), because of its potent anti-inflammatory and chondroprotective actions.

13 Feb 2026

New strategy may improve ovarian cancer treatment outcomes

A new study published by Mayo Clinic researchers suggests that ovarian cancer cells quickly activate a survival response after PARP inhibitor treatment, and blocking this early response may make this class of drugs work better.

12 Feb 2026

Brain circuit links past experiences to appetite control

Our past experiences shape how much we eat and where and what we choose to eat. Using preclinical models, researchers from Mass General Brigham and the Broad Institute of MIT and Harvard have identified brain cells that translate contextual information into appetite control.

12 Feb 2026

Boosting good immune cells can help fight insulin resistance and diabetes

Scientists at the University of Pittsburgh School of Medicine discovered a surprising new way the body can fight insulin resistance and diabetes – by boosting a special type of "good" immune cell in fat tissue.

12 Feb 2026

Early cognitive stimulation preserves memory in Alzheimer’s

A team from the Institute of Neurosciences of the University of Barcelona (UBneuro) has discovered that early and sustained cognitive stimulation can help preserve brain connectivity and memory in Alzheimer's disease, even in advanced stages of the pathology.

12 Feb 2026

New roadmap integrates aging into Parkinson disease models

Even though aging is the largest risk factor for Parkinson's disease, the majority of research aimed at taming the able neurodegenerativeincur motor disease has largely left aging out of the mix.

11 Feb 2026

Alzheimer’s plaques decline after CAR-T immune cell treatment in preclinical study

Researchers engineered CD4+ chimeric antigen receptor T cells targeting fibrillar amyloid beta and tested them in a mouse Alzheimer model. The preclinical study showed reduced amyloid pathology and altered neuroimmune responses, supporting CAR-T immunotherapy as a potential future Alzheimer strategy.

11 Feb 2026